Anti. 🐘
· Researchers state that post-vaccine syndrome is characterized by persistent immune dysregulation & issues with blood coagulation.
· A drug called dapagliflozin, used to treat Type 2 Diabetes, is being investigated for #LongCOVID in a clinical trial.
· A double-blind clinical trial is evaluating an experimental drug called REGN7544 for people with postural orthostatic tachycardia syndrome (POTS).
Anti. 🐘
· A new study that found the risk of Long COVID doubled in children following SARS-C0V-2 reinfection made mainstream headlines this week
· Researchers in Japan may have found a potential biomarker and treatment target for cognitive dysfunction in #LongCOVID
· A new phase 1 clinical trial is currently recruiting to test the GLP-1 agonist drug Liraglutide for Long COVID, multiple sclerosis, and acute leukemia
https://thesicktimes.org/2025/10/07/research-updates-october-7/
Anti. 🐘
· Researchers in Spain assessed over 190,000 participants, found that #LongCOVID prevalence was three to 10 times higher in individuals with three or more reported infections
· A new RECOVER study published in JAMA found that olfactory dysfunction, or changes to sense of smell, occurred in people after SARS-CoV-2 infection
· A behavioral trial at Columbia University (LONG-CALM) is assessing a vague “mindfulness intervention” for Long COVID
https://thesicktimes.org/2025/09/30/research-updates-september-30/
Anti. 🐘
· Two recent studies found limitations of the drug Paxlovid for protection from #LongCOVID, contrasting prior studies that suggested the antiviral drug might help prevent the disease
· Long COVID may increase menstrual bleeding, according to a new survey study published in Nature Communications
· A new clinical trial is testing the supplement Mitoquinone in combination with “exercise rehabilitation” (which may be detrimental) for Long COVID
https://thesicktimes.org/2025/09/23/research-updates-september-23/
Anti. 🐘
· An estimated 36% of people with a documented SARS-CoV-2 infection worldwide have experienced #LongCOVID, according to a new systematic review
· New funding will help advance a potential low-cost diagnostic test for myalgic encephalomyelitis (#ME)
· The SPEAR study group has proposed a potential Long COVID clinical trial with the company’s next-generation monoclonal antibody, VYD2311
https://thesicktimes.org/2025/09/16/research-updates-september-16/
Anti. 🐘
· A medium sized study in Saudi Arabia found that 29% of participants who were infected with SARS-CoV-2 developed #LongCOVID
· In a small case series, a combination of three antivirals was effective in improving symptoms in participants with Long COVID, according to a new preprint
· The Food and Drug Administration (FDA) accepted the drug application of a potential oral therapy for the prevention of #COVID19 following exposure
https://thesicktimes.org/2025/09/09/research-updates-september-9/
Anti. 🐘
· Metformin may help reduce the risk of #LongCOVID, according to two new studies
· A Phase 2 clinical trial is studying the drug vidofludimus calcium (IMU-838) for Long COVID
· The National Institutes of Health’s second RECOVER-Treating Long COVID workshop is happening next week, September 9–10
https://thesicktimes.org/2025/09/02/research-updates-september-2/
Anti. 🐘
· A new preprint from the National Institutes of Health (NIH) RECOVER study found that #COVID19 reinfections may increase risk of #LongCOVID by about 35%
· A new review article in Ageing Research Reviews found that persistent infections from viruses, bacteria, fungus, and parasites can accelerate human aging
· A new Long COVID clinical trial to test the immunotherapy drug Anktiva was announced this week by the Chan Soon-Shiong Institute for Medicine
https://thesicktimes.org/2025/08/19/research-updates-august-19/
Anti. 🐘
· People with myalgic encephalomyelitis (#MECFS) have significant genetic differences in their DNA
· A very small clinical trial of the infusion drug BC 007 published in eClinicalMedicine found “significant improvement” in fatigue in people with #LongCOVID
· A phase 2 clinical trial testing the monoclonal antibody sipavibart is recruiting in Fort Lauderdale, Florida
https://thesicktimes.org/2025/08/12/research-updates-august-12/
Anti. 🐘
· A drug originally developed for celiac disease was found to be safe and effective in treating a post-COVID syndrome in children
· “Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames,” said one of the authors of a new study in Nature
· An upcoming at-home clinical trial program for #LongCOVID, run by Scripps Research, is seeking participants
https://thesicktimes.org/2025/08/05/research-updates-august-5/
Anti. 🐘
· Two studies on potential biomarkers for #MECFS were published this month
· Stellate ganglion blocks, a procedure where an anesthetic is injected into nerves in the neck, may help reduce the severity of some symptoms of #LongCOVID and ME
· An observational study is recruiting 40 people in Boston, Massachusetts to test for defects of air and blood flow in the lungs in people with Long COVID
https://thesicktimes.org/2025/07/29/research-updates-july-29/
Anti. 🐘
· A treatment for cats with a #COVID19-related infection may help advance #LongCOVID research
· The supplement Oxaloacetate may help reduce fatigue for LC, but it “did not reach statistical significance,” according to a new study at Bateman Horne Center
· A new prospective cohort study in JAMA Oncology of 1,572 participants with cancer found that COVID-19 had a “significant impact” on these patients, incl. hospitalization, treatment disruptions, death
https://thesicktimes.org/2025/07/22/research-updates-july-22/
Anti. 🐘
· A new study in PNAS found elevated oxidative stress was a shared characteristic in both #MECFS and #LongCOVID
· RECOVER-Treating Long COVID, the clinical trials initiative run by the Foundation for the NIAID, has announced that it will hold a second annual hybrid workshop discussing the initiative’s research
· A clinical trial in the U.K. called PHOSP-I is recruiting to test the monoclonal antibody Tocilizumab
https://thesicktimes.org/2025/07/15/research-updates-july-15/
Anti. 🐘
· The biotech company Invivyd, which makes the #COVID19 monoclonal antibody Pemgarda, announced that it has launched the SPEAR Study Group to explore the drug for #LongCOVID and post-vaccine syndrome (PVS)
· A new study from Taiwan published in Pediatrics and Neonatology found about 14% of children developed Long COVID after being infected with #SarsCoV2
· A new observational study is investigating the relationship between COVID-19 and #Diabetes
https://thesicktimes.org/2025/07/08/research-updates-july-8/
Anti. 🐘
· Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease
· A recent preprint shared in medRxiv found further evidence of brain damage after COVID-19
· A new clinical trial for myalgic encephalomyelitis (ME) is recruiting in Tokyo, Japan, to test the monoclonal antibody Rituximab
https://thesicktimes.org/2025/07/01/research-updates-july-1/
Anti. 🐘
· A new review paper published in Psychiatry and Clinical Neurosciences focuses on how Long COVID impacts the nervous and immune systems
· Another study has found potential biomarkers in the blood of people with myalgic encephalomyelitis (ME)
· The Patient-Led Research Collaborative (PLRC) launched a new clinical trial and research study platform for Long COVID and associated diseases: the PLRC Registry
https://thesicktimes.org/2025/06/24/research-updates-june-24/
Anti. 🐘
· Pregnant people infected with SARS-CoV-2 during first trimester more likely to have smaller newborns
· Children with multisystem inflammatory syndrome (MIS-C) triggered by COVID-19 had metabolic disturbances that “mirrored those seen in severe adult #COVID19 patients
· A population-level study from a database in Utah found there was a significant association between a past COVID-19 diagnosis and self-harming in children and adolescents
https://thesicktimes.org/2025/06/17/research-updates-june-17/
Anti. 🐘
· Three recent studies show the harmful effects of misdiagnosis for chronic diseases and conditions
· A new preprint shared in Research Square found a connection between post-exertional malaise (PEM) and microclots, or tiny blood clots that disrupt how oxygen moves through the body
· The Cohen Center for Recovery from Complex Chronic Illness (CoRE) at Mount Sinai in New York is now recruiting for their rapamycin clinical trial for #LongCOVID
https://thesicktimes.org/2025/06/10/research-updates-june-10/
Anti. 🐘
· New NIH study found that around one in seven children under age six with a prior SARS-CoV-2 infection met the probable diagnostic criteria for #LongCOVID
· Pemivibart (Pemgarda), a monoclonal antibody that helps prevent COVID-19, was found to be “well tolerated” and effective in phase 3 clinical trial
· New preprint from researchers in the US & Canada used a model called “Mobius” to classify ME & Long COVID with 97% accuracy, using data from blood
https://thesicktimes.org/2025/06/03/research-updates-june-3/
Anti. 🐘
· A large study in Nature Genetics found a genetic risk factor for developing #LongCOVID
· Leading Long COVID and myalgic encephalomyelitis (ME) researchers have pushed back against an op-ed commissioned by the BMJ that spread false claims about #MECFS
· RECOVER-Treating Long COVID (TLC), the clinical trials initiative from the National Institutes of Health’s flagship Long COVID research program, shared updates about forthcoming trials
https://thesicktimes.org/2025/05/27/research-updates-may-27/
Anti. 🐘
· #LongCOVID clinical trial assessing the monoclonal antibody AER002 found no difference between those who got the drug and placebo
· prospective study in Pediatric International found that, six months after SARS-C0V-2 infection, 23% of children had Long COVID symptoms
· Chinese study of five participants with Long COVID and myocarditis found severe damage in the mitochondria
https://thesicktimes.org/2025/05/20/research-updates-may-20/
Anti. 🐘
· The Bateman Horne Center and Open Medicine Foundation recently released a highly anticipated ME and Long COVID clinical care guide.
· Researchers estimate a higher rate of new-onset diabetes after SARS-C0V-2 infection in a systematic review in Emerging Microbes and Infections
· A new preprint in Medxriv further demonstrates that Long COVID and ME are not deconditioning.
https://thesicktimes.org/2025/05/13/research-updates-may-13/
GNU social JP is a social network, courtesy of GNU social JP管理人. It runs on GNU social, version 2.0.2-dev, available under the GNU Affero General Public License.
All GNU social JP content and data are available under the Creative Commons Attribution 3.0 license.